<DOC>
	<DOC>NCT00310531</DOC>
	<brief_summary>The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of osteoporosis.</brief_summary>
	<brief_title>3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Last (regular) menstrual period more than 5 years ago Relative good state of health Intact, normal uterus Bone and musculoskeletal diseases Clinically significant vertebral fracture within the last 12 months Preexisting cardiovascular disease (e.g. uncontrolled high/low blood pressure, stroke, thromboembolic event etc) Uncontrolled diabetes mellitus (or treated with insulin) Uncontrolled thyroid disorders Relevant renal disorder or significant liver dysfunction (including cholestasis) History of alcohol or drug abuse History of immobilization of more than 2 months in the last 6 months Smoking of more than 10 cigarettes per day Unexplained uterine bleeding Known or suspected malignant or premalignant disease (e.g. cancer of breast or uterus, melanoma)</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>